Review

Effects of adding exercise to usual care in patients with either hypertension, type 2 diabetes or cardiovascular disease: a systematic review with meta-analysis and trial sequential analysis

Anupa Rijal (a), ^{1,2} Emil Eik Nielsen (b), ^{1,2} Tara Ballav Adhikari (b), ³ Sarmila Dhakal,⁴ Mathias Maagaard (b), ⁵ Reza Piri (b), ^{6,7} Dinesh Neupane (b), ⁸ Peter Haulund Gæde,¹ Michael Hecht Olsen, ^{1,2} Janus Christian Jakobsen (b) ^{1,9}

ABSTRACT

Objective To assess the beneficial and harmful effects of adding exercise to usual care for people with hypertension, type 2 diabetes mellitus and/or cardiovascular disease.

Design Systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. **Data sources** The CENTRAL, MEDLINE, EMBASE,

Science Citation Index Expanded on Web of Science and BIOSIS searched from inception to July 2020.

Eligibility criteria for selecting studies We included all randomised clinical trials adding any form of trialist defined exercise to usual care versus usual care in participants with either hypertension, type 2 diabetes or cardiovascular disease irrespective of setting, publication status, year and language.

Outcome and measures The primary outcomes were all-cause mortality, serious adverse events and quality of life.

Data extraction and synthesis Five independent reviewers extracted data and assessed risk of bias in pairs. Our methodology was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses, Grading of Recommendations Assessment, Development and Evaluation and Cochrane Risk of Bias-version 1.

Results We included 950 trials, of which 248 trials randomising 21 633 participants reported on our predefined outcomes. All included trials were at high risk of bias. The major types of exercise reported were dynamic aerobic exercise (126/248 trials), dynamic resistance exercise (25/248 trials), and combined aerobic and resistance exercise (58/248 trials). The study participants were included due to cardiovascular diseases (189/248 trials), type 2 diabetes (41/248 trials) or hypertension (16/248 trials). The median intervention period was 3 months (IQR: 2–4 months) and the median follow-up period was 6 months (IQR:

3–8 months) after randomisation. Meta-analyses and trial sequential analyses showed evidence of a beneficial effect of adding exercise to usual care when assessing all-cause mortality (risk ratio (RR) 0.82; 95% CI 0.73 to 0.93; I^2 =0%, moderate certainty of evidence) and serious adverse events (RR 0.79; 95% CI 0.71 to 0.88; I^2 =0%, moderate certainty of evidence). We did not find evidence of a difference between trials from different economic regions, type of participants, type of exercise or duration of follow-up. Quality of life was assessed using several different tools, but the results generally showed that exercise improved quality of

WHAT IS ALREADY KNOWN?

- ⇒ Previous individual trials have been underpowered to investigate the effects of adding exercise intervention to usual care on major clinical outcomes
- ⇒ Previous reviews have focused on selected types of exercise and narrow patient groups leading to loss of power and conflicting results.

WHAT ARE THE NEW FINDINGS?

- ⇒ A short duration of any type of exercise seems to reduce the risk of all-cause mortality and serious adverse events in patients with either hypertension, type 2 diabetes or cardiovascular diseases.
- ⇒ Exercise has significant effect on quality of life but seems clinically minimal.
- ⇒ Our results show that adding exercise to usual care seems to be beneficial and could be prescribed globally as a supplemental to nonpharmacological intervention to all patients with either hypertension, type 2 diabetes or cardiovascular disease.

Br J Sports Med: first published as 10.1136/bjsports-2022-106002 on 30 November 2022. Downloaded from http://bjsm.bmj.com/ on November 30, 2023 at Kobenhavns Universitets Bibliotek. Protected by copyright.

life, but the effect sizes were below our predefined minimal important difference.

Conclusions A short duration of any type of exercise seems to reduce the risk of all-cause mortality and serious adverse events in patients with either hypertension, type 2 diabetes or cardiovascular diseases. Exercise seems to have statistically significant effects on quality of life, but the effect sizes seem minimal. **PROSPERO registration number** CRD42019142313.

INTRODUCTION

In 2019, nearly 18.6 million deaths were due to cardiovascular disease worldwide.¹ The two leading comorbidities and risk factors of cardiovascular disease are hypertension and type 2 diabetes. The complications of hypertension and type 2 diabetes are linked with developing macrovascular and microvascular diseases, leading to cardiovascular adverse events and related deaths.²⁻⁴ Currently, an estimated 1.4 billion adults are living with hypertension. Likewise, type 2 diabetes is

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/bjsports-2022-106002).

For numbered affiliations see end of article.

Correspondence to

Anupa Rijal, Department of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark; anuparijal@gmail.com

Accepted 31 October 2022 Published Online First 30 November 2022

Check for updates

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Rijal A, Nielsen EE, Adhikari TB, *et al. Br J Sports Med* 2023;**57**:930–939.



the seventh-leading cause of disability-adjusted life-years worldwide,⁵ accounting for 1.5 million deaths in 2019.⁶ The substantial burden of these diseases is disproportionately high in low-income and middle-income countries.⁵⁷⁸

Despite well-documented evidence-based treatment and management strategies, the control of hypertension, type 2 diabetes and cardiovascular disease is suboptimal.^{5 9} The intricate linkage of physical inactivity and sedentary lifestyle plays a substantial role in propagating the burden of these noncommunicable diseases.^{4 9 10} Consequently, exercise is among the most recommended lifestyle interventions for secondary and tertiary prevention and management of hypertension, type 2 diabetes and cardiovascular diseases.¹¹⁻¹³ Exercise exists in different forms.¹⁴ Based on involvement of muscle activity, intensity and frequency, it can be either dynamic or static. Dynamic aerobic exercise, dynamic resistance exercise and combined aerobic and resistance exercise are some of the common forms of exercise recommended for manangement of various noncommunicable disease.¹⁵ Apart from this isometric (static) resistance exercise, yoga and other balance and flexibility enhancing exercises are being practised throughout the globe.

The European Society of Cardiology,¹⁶ the American Diabetes Association,¹⁷ the American Heart Association¹⁵ have recommended moderate to vigorous physical activity, primarily aerobic and resistance exercises, 3-5 times per week for patients with hypertension, type 2 diabetes or cardiovascular diseases. However, the evidence behind these recommendations and the choice of type of exercise, including the duration and intensity of the exercise, is not well documented. Various systematic reviews and meta-analyses of randomised trials have shown beneficial effects of exercises in (1) reducing cardiovascular risk factors such as elevated blood pressure, glucose intolerance and hyperlipidaemia,¹⁸⁻²² (2) improving motor and cardiorespiratory functions²³²⁴ and (3) improving morphological composition.^{13 14} Only non-randomised studies have documented that exercise reduces the risk of death.^{25–27} Randomised clinical trials on the effects of exercise in the prevention of mortality, serious adverse events (SAEs) and other clinical outcomes remain inconclusive.²⁸⁻³⁰ Previous reviews on the beneficial effects of exercise on improving quality of life also remain uncertain, primarily due to smaller trials with potential biases.^{24 31-33}

No prior systematic reviews have pooled trials assessing any form of exercise as secondary or tertiary prevention in participants with either hypertension, type 2 diabetes or cardiovascular disease,taking into account both random and systematic errors.¹⁴

In this systematic review with meta-analysis and trial sequential analysis, we aim to assess the beneficial and harmful effect of adding exercise to usual care in patients with hypertension, type 2 diabetes and cardiovascular diseases.

METHODS

Our review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for reporting systematic reviews evaluating interventions in health-care.³⁴ The methodology has been described in detail in our prepublished protocol registered prior to the systematic literature search.¹⁴

Search strategy and selection criteria

In brief, we included all randomised clinical trials assessing the effects of adding exercise (as defined by trialists) to usual care (as defined by trialists-any routine care received by the patients) versus usual care (same usual care as in the intervention group) in patients with either hypertension, type 2 diabetes or cardiovascular disease. Trials were included irrespective of setting, trial duration, publication status, publication year and language. We searched from their inception to July 2020 in the Cochrane Central Register of Controlled Trials (CENTRAL), Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (EMBASE), Science Citation Index Expanded on Web of Science, BIOSIS, Google Scholar and ClinicalTrials.gov. The detailed search strategy can be found in online supplemental S1 text. In addition, we manually searched reference lists of previously published reviews.

Data collection and risk of bias

Five authors (AR, TBA, SD, MM and RP) independently extracted data using a standardised data extraction sheet and assessed risk of bias using the Cochrane Risk of Bias-version 1 (RoB1)³⁵ in pairs. The following bias domains were assessed: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, for profit bias and other risks of bias. Any disagreements were resolved through discussion with a third author (JCJ or EEN). We contacted authors of all trials via email to retrieve missing information and individual patient data and to access full text wherever necessary. The email was sent to corresponding author only once and for authors whose email was outdated or not available we searched for research gate profile accessed through their name and wrote an individual private message regarding the same.

Outcomes and subgroup analyses

Our primary outcomes were all-cause mortality, SAEs and quality of life. SAEs are defined as proportion of participants with an SAE defined as any untoward medical occurrence that resulted in death; was life threatening; was persistent; or led to significant disability, nephrotoxicity, superinfection, need for respiratory support, need for circulatory support or prolonged hospitalisation or as defined by International Council for Harmonisation guideline for Good Clinical Practice guidelines or as referred by trialists.^{14 36} The secondary outcomes were cardiovascular mortality, myocardial infarction and stroke.¹⁴ For all outcomes, we used trial results reported to the longest follow-up.

The secondary outcomes blood pressure (systolic and diastolic both) and microvascular complications as mentioned in protocol are not reported in this article. We plan to discuss effect of exercise on blood pressure separately in another article due to share volume of data which if included would have been difficult to present and summarise in this paper. For microvascular complications, we did not find any data to report.

We planned several subgroup analyses (see the Results section): (1) different types of exercise (as defined by trialists), (2) different disease group—hypertension, type 2 diabetes and cardiovascular disease (as defined by trialists); cardiovascular disease as defined by WHO includes cerebrovascular disease, rheumatic heart disease, deep vein thrombosis, pulmonary thrombosis, coronary artery disease such as myocardial infarction and heart failure,³⁷ (3) high-income countries versus low-income and middle-income countries (as defined by The World Bank country classification),³⁸ (4) trials at high risk of bias compared with trials at low risk of bias.¹⁴ In addition, we added two post hoc subgroup analyses: (1) trials including biological male compared with biological female compared with trials including both biological

genders and (2) short-term follow-up (≤median follow-up) compared with long-term follow-up (>median follow-up).

Data analysis

We used and STATA V.17 (StataCorp) for all statistical analyses.³⁹ We assessed three primary outcomes, and therefore, we considered a p value of 0.025 as the threshold for statistical significance for primary outcomes and 0.05 for secondary outcomes.¹⁴ We conducted both fixed-effect and random-effect meta-analysis and primarily reported the most conservative result and considered the less conservative results as a sensitivity analysis.^{14 40} We analysed different quality of life scales separately to avoid the methodological problems with using standardised mean difference.⁴¹ The predetermined minimal important difference for quality of life scales was used, calculated as the mean difference of the observed SD divided by two in the control group.⁴² We investigated possible heterogeneity by visual inspection of forest plots, by calculating inconsistency (I² and by performing subgroup analysis (test of interaction). We assessed small study bias through funnel plots. We performed trial sequential analysis to control for the risks of type I errors and type II errors.⁴³ We

used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence.^{44 45} Further, we also conducted a separate GRADE rating for type of participants and type of exercise.

RESULTS

Study characteristics

Based on our literature search on 6 July 2020, we identified 32 739 references through databases search and 531 references via Google Scholar, ClinicalTrials.gov and previous meta-analysis. We excluded 10 484 reference duplicates. Thus, we screened 22 786 records and excluded 20 525 based on titles and abstract. We assessed 2261 full text for eligibility. Of these, we could not find the full text for 62 studies. We excluded 990 studies based on our inclusion and exclusion criteria. This resulted in 1272 publications reporting the results of 950 trials. A total of 248 trials randomising 21 633 participants reported on all-cause mortality, SAEs, quality of life and/or other clinical events (figure 1).

The characteristics of the included trials are summarised in online supplemental S1 table. Most trials (219/248; 88%)



Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.

Table 1 Summary of characteristics of include	ed studies			
Study characteristics	n (%)			
Gender (n=248)				
Trials with male participants only	23 (9.3)			
Trials with female participants only	6 (2.4)			
Trials with both male and female participants	219 (88.3)			
Type of participants (n=248)				
Cardiovascular disease	189 (76.2)			
Type 2 diabetes	41 (16.5)			
Hypertension	16 (6.5)			
Cardiovascular disease+type 2 diabetes	2 (0.8)			
Trials from economic region (n=248)				
High income countries	205 (82.6)			
Low-income and middle-income countries	43 (17.3)			
Type of exercise intervention (n=248)				
Dynamic aerobic exercise	126 (50.8)			
Dynamic resistance exercise	25 (10.1)			
Combined exercise	58 (23.4)			
Body mind therapies	25 (10.1)			
Inspiratory muscle training	4 (1.6)			
Isometric resistance exercise	2 (0.8)			
Stroke functional exercise	8 (3.2)			
Median exercise intervention period (n=248)	3 months (IQR: 2-4 months)			
Median follow-up period (n=248)	6 months (IQR: 3-8 months)			
Median volume of exercise (n=162)	135 min/week (IQR: 90–180 min/week)			
IQR, Inter-Quartile Range.				

included both male and female participants. The number of participants in each trial ranged from 14^{46 47} to 2331.⁴⁸ The median intervention period was 3 months (IQR: 2 –4 months) and the median follow-up period was 6 months (IQR: 3–8 months). Most trials (189/248; 76%) included participants with cardiovascular diseases, followed by trials including participants with type 2 diabetes (41/248; 17%) and hypertension (16/248;

7%). The experimental interventions were dynamic aerobic exercise in (126/248; 51%) trials, combined aerobic and resistance exercise in 58/248 (23%) trials, dynamic resistance exercise in (25/248; 10%) trials and body-mind therapies in 25/248 (10%). The median duration of the exercise interventions was 135 min/week (IQR: 90–180 min/week) (table 1). The majority of the included trials (205/248; 83%) were conducted in high-income countries, and only (43/248; 17%) trials were conducted in low-income and middle-income countries.

Table 2 summarises the baseline characteristics of the included participants.

Primary outcomes

All-cause mortality

Ninety-eight trials randomising 12 976 participants reported on all-cause mortality. A total of 434 of 6649 (6.5%) participants randomised to exercise died compared with 525 of 6327 (8.3%) control participants. The median assessment time point was at 6 months (IQR: 3-12 months) after randomisation. Meta-analysis showed evidence of a beneficial effect of adding exercise to the usual care (risk ratio, RR 0.82; 95% CI 0.73 to 0.93; p=0.0014). Visual inspection of forest plot (figure 2) and I^2 statistics indicated no statistical heterogeneity ($I^2=0\%$). Trial sequential analysis showed that there was enough information to confirm that exercise compared with control reduced the risk of death by 18% (figure 3). We assessed this outcome results as high risk of bias (online supplemental S1 figure) and the certainty of the evidence as moderate (table 3). Funnel plot indicated no small study bias (online supplemental S2 figure). None of our preplanned subgroup analyses showed evidence of a difference (figure 4).

Serious adverse events

One hundred and fifty trials randomising 16 241 participants reported on SAEs. A total of 578 of 8473 (6.8%) participants

Table 2 Baseline characteristics of included studies							
	Trials providing information	Intervention	No analysed (intervention)	Usual care	No analysed (usual care)		
Age—years (SD)	228	60.79 (6.3)	8468	59.43 (8.5)	7386		
Male sex—n (%)	221	6468 (65.2)	9926	5869 (67.2)	8737		
Female sex—n (%)	221	3458 (34.8)	9926	2868 (32.8)	8737		
BMI	82	29.45 (4.5)	2656	31.07 (4.3)	2269		
Baseline medications n (%)							
Anti hypertensive drugs(not classified)	25	919 (65.1)	1412	570 (51.1)	1115		
Beta-blockers	97	3324 (66.0)	3165	3201 (67.3)	4705		
Diuretics	76	2763 (70.4)	3923	2352 (64.6)	3639		
ACEI	91	3304 (75.6)	4368	3088 (76.5)	4039		
Calcium channel blockers	31	332 (24.1)	1377	300 (24.2)	1242		
Nitrates	32	579 (44.2)	1310	517 (42.5)	1216		
ARB	12	145 (39.3)	369	121 (34.8)	348		
Digitalis	12	116 (23.0)	505	119 (25.1)	475		
Diagoxin	30	887 (42.7)	2076	891 (43.7)	2041		
Aspirin (anticoagulant)	20	569 (69.1)	823	576 (73.4)	785		
Acetylsalycylic acid	4	109 (90.1)	121	108 (93.9)	115		
Lipid lowering drugs (statin, fibrate, omega)	41	994 (52.4)	1898	740 (46.5)	1590		
Glycaemic control							
Metformin	4	300 (70.1)	428	292 (76.2)	383		
Insulin	15	112 (14.3)	781	91 (15.7)	579		
Oral hypoglycaemic agents (OHA)	15	600 (69)	869	429 (68.5)	626		
Insulin+OHA	8	196 (28.8)	681	127 (23.3)	545		
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index.							

Charling	Study	Interve Events	ention Total	Con Events	itrol Total		RR with 95% CI	Weight (%)
CTM11200000017200 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ACTRN12608000263392	3	137	10	128		0.30 [0.08, 1.05]	0.88
Charly 20000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ACTRN12609000437268	1	66	1	64		0.97 [0.06, 15.19]	0.19
bank A 1001 construct GoV construct	ACTRN12610000096055 Aronov D 2015	0	96 194	2	91 189		0.19[0.01, 3.98]	0.16
Barrow E COV 1 31 2 30 D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D <	Babu A 2019	0	42	1	41		0.33 [0.01, 7.96]	0.14
Sackade in 1902 Sackade in	Barrow DE 2007	1	31	2	31	<u> </u>	0.52 [0.05, 5.41]	0.26
samell 1990 7 100 0 000 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20	Belardinelli R 1999 Bertie J 1992	9	41 57	20 3	29 50		0.44 [0.22, 0.87]	3.06 0.16
Baruff 19/4130222222221100000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000	Bethell H 1990	7	106	8	108	-	0.90 [0.34, 2.40]	1.48
Jamental Jobo J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J J <thj< th=""> <thj< th=""> <thj< th=""> <thj< td=""><td>Bjernulf A 1974</td><td>1</td><td>33</td><td>0</td><td>29</td><td></td><td>2.57 [0.11, 60.81]</td><td>0.14</td></thj<></thj<></thj<></thj<>	Bjernulf A 1974	1	33	0	29		2.57 [0.11, 60.81]	0.14
baske 0.97 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87 <t< td=""><td>Blumenthal J 2005 Borland M 2014</td><td>1</td><td>47 23</td><td>2</td><td>42 21</td><td></td><td>- 2.63 [0.11, 62.95] 0.92 [0.14, 6.01]</td><td>0.14</td></t<>	Blumenthal J 2005 Borland M 2014	1	47 23	2	42 21		- 2.63 [0.11, 62.95] 0.92 [0.14, 6.01]	0.14
basell 210 10 11 10 11 10 11 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 <t< td=""><td>Brubaker P 2009</td><td>1</td><td>29</td><td>1</td><td>28</td><td></td><td>0.97 [0.06, 14.74]</td><td>0.19</td></t<>	Brubaker P 2009	1	29	1	28		0.97 [0.06, 14.74]	0.19
Jamon Pind2 12 130 1 34 - 0.88 [0.20, 1.93 1.41 0.44 [0.2, 0.99] 0.15 South Act 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <td>Brunelli S 2019</td> <td>1</td> <td>15</td> <td>1</td> <td>20</td> <td><u> </u></td> <td>1.31 [0.09, 19.42]</td> <td>0.20</td>	Brunelli S 2019	1	15	1	20	<u> </u>	1.31 [0.09, 19.42]	0.20
	Carson P 1982 Chen DM 2018	12	139 31	21	131 34		0.58 [0.29, 1.13]	3.14 0.14
Datable 2001 C D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D D <thd< th=""> D D D D D D D D D D D D D D D D D D D D D D D D D D <thd< th=""> D D D D D D D D D D D D D D D D D D D D D D D <thd< th=""> D <thd< th=""> <thd< <="" td=""><td>Coats AJ 1992</td><td>0</td><td>8</td><td>1</td><td>10</td><td></td><td>0.44 [0.02, 9.69]</td><td>0.15</td></thd<></thd<></thd<></thd<></thd<>	Coats AJ 1992	0	8	1	10		0.44 [0.02, 9.69]	0.15
Drankskor 2 4 0 3 2 2 2 2 1 1 2 1 1 2 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Doletsky A 2018	0	24	2	20		0.18 [0.01, 3.63]	0.16
Same Data Data Data Data Data Data Data Dat	Donaldson C 2009a	2	4	0	3		2.86 [0.18, 45.91]	0.18
ngbor 1992 2 103 4 60	EAMI Study	2	49	1	51		2.04 [0.19, 21.80]	0.25
Techne B1984 3 8 4 4 0 0 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80	Engblom E 1992	2	103	4	96		0.48 [0.09, 2.54]	0.51
Inscription Image Image <thimage< th=""> Image Image</thimage<>	Fletcher BJ 1994	3	38	4	43		0.86 [0.20, 3.62]	0.69
any R 2010h 0 1 0 17 2.7 (0.11, 50.30) 0.11 (0.11, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.71) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11 (0.01, 7.72) 0.11	Froelicher V 1985	0	28	1	24		0.30 [0.01, 7.02]	0.14
Sam R 2010b 0 17 1 15 0.31 (0.1., 2.1) 0.14 Sam R 2010b 1 16 0 16 2.31 (0.1., 2.1) 0.14 Sam R 2010b 1 16 0 16 2.31 (0.1., 2.1) 0.14 Sam R 2010b 1 16 0 16 2.31 (0.1., 2.1) 0.14 Sam R 2010b 1 10 0 2.31 (0.1., 2.1) 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.17 0.11 0.14 0.11 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.15 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14 0.14	Gary R 2010a	1	19	0	17		2.57 [0.11, 59.30]	0.14
Jamuar Double State Construction Construction Construction Construction Intractioner R19905 1 44 42 Construction Constructio	Gary R 2010b	0	17	1	15		0.31 [0.01, 7.21]	0.14
Number Name No No No No No Arannevent R 1995 1 1 1 0 0 0.06 (1.400) 0.15 Arannevent R 1995 1 1 0 0 0.24 (0.11, 50.23 0.5 Arannevent R 1995 1 2.3 1 2.9 0.45 (0.07, 1.877) 0.21 Arannevent R 2000-Eth S 2000 3 3.0 2.1 2.9 0.45 (0.05, 1.891) 0.16 RCT206027/0.085N1 4 3.0 0.2 1.55 (0.27, 876) 0.45 SRCTM65077205 3 3.0 0.2 1.55 (0.16, 4.71) 0.16 SRCTM65077205 1 4.5 1 4.3 0.67 (0.16, 1.501) 0.16 GascLaurer M 2000 1 4.5 1 4.3 0.67 (0.01, 1.45) 0.16 Aranjaharmer B 2000 1.5 1.4 3.00 (0.12, 7.54) 0.44 0.67 (0.02, 3.37) 1.06 Aranjaharmer B 2000 1.6 1.7 7 7 5 7 1.119	Giannuzzi P 2003/ELVD-CHF Gottlieb S 1999	0	45 16	1	44 16		0.33 [0.01, 7.97]	0.14
shamberd R1 1905 1 1 0 10 2.54 [0.11, 65.20 0.15 shamberd R1 2000-Eb 0 2003 3 3 2 35 1.54 [0.27, 8.69] 0.46 Shamberd R1 2000-Eb 0 2003 3 3 2 25 1.55 [0.15, 8.07] 0.15 [0.15, 8.07] 0.15 [0.15, 8.07] 0.15 [0.15, 8.07] 0.15 [0.15, 8.07] 0.15 [0.15, 8.07] 0.15 [0.15, 8.07] 0.15 [0.15, 8.07] 0.15 [0.15, 8.07] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8.7] 0.16 [0.16, 8	Hambrecht R 1993	1	44	1	42		0.96 [0.06, 14.80]	0.19
stambersch R 1996 1 9 1 9 1 100 10.07 12.77 869 0.40 CR12016922700858N1 1 20 0.43 0.02.7 18.97 0.43 0.02.7 18.97 0.43 0.02.7 18.97 0.43 0.02.7 18.97 0.43 0.02 10.01 0.06 15.91 0.14 0.05 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070 0.070	Hambrecht R 1995	1	11	0	10		2.54 [0.11, 56.25]	0.15
Americanic Section 2 and	Hambrecht R 1998	1	9	1	9 35		1.00 [0.07, 13.87]	0.21
Rel To 1982 70.0858N1 4 0 25 2 2 6 1 0 0 0 0 0 15 5 1 0 19 SRCTM6072026 3 0 0 2 5 2 7 0 0 4 0 0 0 0 1 0 0 0 0 15 5 1 0 19 SRCTM615556 7 7 7 5 6 0 1 1 42 0 0 16 1 0 5 0 16 6 77 0 4 1 det visit 2005 1 4 5 1 4 3 0 0 6 0 0 0 1 1 42 0 0 1 1 42 0 0 1 1 42 0 0 1 1 43 0 1 43 anghormen 2 2008 1 3 4 6 3 4 0 0 7 0 10 1 0 0 2 1 5 1 0 4 1 det visit 2008 1 3 6 8 6 2 0 0 3 0 0 1 7 8 1 0 19 0 0 2 1 5 1 0 4 1 det visit 2008 1 3 6 8 6 2 0 0 3 0 0 1 7 8 1 0 19 0 0 2 1 5 1 0 4 1 det visit 2008 1 3 6 8 6 2 0 0 3 0 0 1 7 8 1 0 19 0 0 2 1 5 1 0 4 1 det visit 2008 1 3 6 8 6 2 0 0 3 0 0 1 7 8 0 0 7 0 3 0 0 10 1 0 0 2 1 5 1 0 4 1 det visit 2008 1 3 6 8 6 2 0 0 3 0 0 1 19 0 0 2 1 5 1 0 4 1 det visit 2008 1 3 6 8 7 5 5 7 5 det visit 2 0 0 3 0 0 7 2 0 0 7 0 0 0 7 0 0 0 7 0 0 0 1 0 0 0 2 1 2 0 4 1 0 0 0 0 1 0 0 2 1 2 0 4 1 0 0 0 0 1 0 0 0 2 1 0 0 0 0 0 1 0 0 0 0	Hung J 1984	0	23	2	35 29		0.43 [0.02, 10.11]	0.40
BRCTM60/2023 1 302 1 502 1 100 [0.60, 16.91] 0.16 SRCTM50/7026 3 66 4 32 52 153 0.27, 8.78 0.46 SRCTM50/7026 1 9 2 20 1.06 [0.61, 16.37] 0.41 SRCTM50/7026 1 45 1 43 0.96 [0.61, 16.37] 0.41 SRCTM50/7026 1 45 1 43 0.96 [0.61, 14.3] 1.16 1.16 0.16 0.17 1.16 1.781 0.14 0.33 [0.10, 13.4] 0.16 0.17 1.16 1.17 1.16 0.16 0.17 1.16 0.16 0.11 1.16 0.16 0.11 0.16 0.11 0.16 0.11 0.16 0.11 0.16 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11<	IRCT20180827040885N1	4	25	2	26	—	1.93 [0.38, 9.72]	0.54
sn. (n. mo.y.ucbo) 3 3 36 4 34 4 34 0.73 [0.16, 3.06] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 14.8, 30.6] 0.70, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6, 30.6,	ISRCTN04252749	1	302	1	302		1.00 [0.06, 15.91]	0.19
2 1 2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	ISRC1 N50570295 ISRCTN51615566	3	36 50	4	34 52		0.73[0.18, 3.05] 1.53[0.27 8.78]	0.70 0.46
io rask: mix 2006 2 1 45 1 43 0.65 [0.16, 6.143] 0.14 Gate-lawer A 2002 6 43 12 34 0.33 [0.01, 7.81] 0.13 a Rovie M 2002 6 43 12 34 0.97 [0.02, 1.51] 0.33 a Rovie M 2002 6 43 12 34 0.97 [0.02, 1.51] 0.33 a Rovie M 2002 6 43 12 34 0.97 [0.02, 1.51] 0.33 a Collo 1.7 78 0.7 79 300 [0.12, 7.24] 0.44 Ac 2016 6 75 5 75 1.19 [0.26, 1.51] 0.33 0.65 0.37 [0.16, 1.64, 287 0.41 VCT0047437 188 57 1.5 75 0.42 [0.02, 1.51] 0.42 [0.02, 1.51] 0.42 [0.02, 1.51] 0.45 [0.02, 1.64] 0.42 [0.02, 1.51] 0.5 [0.02, 1.64] 0.42 [0.02, 1.51] 0.5 [0.02, 1.64] 0.42 [0.02, 1.51] 0.5 [0.02, 1.64] 0.42 [0.02, 1.51] 0.5 [0.02, 1.64] 0.5 [0.02, 1.64] 0.5 [0.02, 1.64] 0.5 [0.02, 1.64]	ISRCTN68886157	7	77	5	80		1.42 [0.47, 4.29]	1.16
Sabe-Lauren M 2003 1 45 1 43 0.66 [0.06, 14.83] 0.18 a. Rovere M 2002 6 43 12 34 0.47 [0.19, 1.19] 1.78 a. Rovere M 2002 6 43 12 34 0.87 [0.10, 1.73] 0.14 a. Rovere M 2002 6 43 12 34 0.97 [0.10, 1.34] 0.83 a. La Zo18 1 75 5 1.19 [0.28, 3.73] 1.08 Merals 1085 6 75 5 1.43 [0.25, 8.23] 0.48 CCT0007437 189 70 187 0.87 [0.00, 1.16] 4.28 CCT00176394 1 138 1 71 0.52 [0.03, 8.16] 0.14 CCT00245919a 1 138 1 71 0.52 [0.01, 3.22] 0.51 CCT00245919a 1 138 1 72 4.02 [0.01, 3.22] 0.51 CCT0064551 1 40 1.1 50 0.32 [0.01, 3.25] 0.90 CCT00645520 h 4 <td>Jo'nsdo' ttir 2006</td> <td>2</td> <td>19</td> <td>2</td> <td>20</td> <td></td> <td>1.05 [0.16, 6.77]</td> <td>0.41</td>	Jo'nsdo' ttir 2006	2	19	2	20		1.05 [0.16, 6.77]	0.41
anayura N 1989 0 2 1 24 0.51 (0.01, 75] (0.18, 1.15] 1.78 angharmer B 2008 1 34 6 34 0.19 (0.02, 1.51) 0.33 um 2016 3 6 8 6 0.57 (1.01, 1.34) 0.18 um 2016 3 6 8 6 0.57 (1.01, 1.34) 0.38 um 2016 3 5 2 5 75 1.19 (0.28, 0.373) 0.68 UCT0047437 188 670 18 1 18 0.52 (0.02, 6.09) 0.14 UCT00214513 2 3 4 26 0.42 (0.02, 2.12) 0.54 UCT00249196 3 123 0 72 4.02 (0.21, 7.56) 0.16 UCT00249196 3 123 0 72 4.02 (0.21, 7.56) 0.16 UCT00249196 3 123 0 72 4.02 (0.21, 7.56) 0.16 UCT002459196 4 7 2 0.73 (0.21, 2.55) 0.90 <t< td=""><td>Katz-Leurer M 2003</td><td>1</td><td>45</td><td>1</td><td>43</td><td></td><td>0.96 [0.06, 14.83]</td><td>0.19</td></t<>	Katz-Leurer M 2003	1	45	1	43		0.96 [0.06, 14.83]	0.19
anghammer B 2008 1 34 6 34 0.19 [0.02, 1.51] 0.33 Lin M 2018 3 66 6 75 75 0.37 [0.10, 1.34] 0.88 Adra S 1985 6 75 5 75 1.19 [0.33, 3.73] 108 Mara S 1985 6 75 5 75 1.19 [0.33, 3.73] 108 NCT00047437 189 970 198 974 0.97 [0.80, 1.16] 42.87 NCT0024311 1 2 34 4 26 0.42 [0.00, 2.12] 0.54 NCT002431916 1 36 72 4.02 [0.21, 76.81] 0.16 0.16 NCT002439196 1 35 14 0.88 [0.22, 2.01] 0.16 0.52 [0.03, 6.16] 0.16 NCT002439196 1 2 2 0.73 [0.21, 2.55] 0.90 NCT002439196 1 4 7 2 2 0.73 [0.21, 2.55] 0.90 NCT002439196 4 7 2 2 0.73 [0.21, 2.55] 0.90 NCT0025555 1 8 1 <	La Rovere M 2002	6	43	12	24 34		0.33[0.01, 7.81]	1.78
Lim M 2016 3 66 8 62 0.37 [0.10, 1.34] 0.88 Alarra S 1985 6 75 5 75 75 119 [0.38, 3.73] 1.08 Moreland JD 2003 3 55 75 75 75 75 75 119 [0.38, 3.73] 1.08 Moreland JD 2003 3 55 75 75 75 75 75 119 [0.38, 3.73] 1.08 VCT00174351 1 29 0 32 315 [0.14, 7.54 [0.14 42.87 0.42 [0.06, 2.12] 0.54 VCT0024513 2 34 4 26 0.42 [0.21, 7.65,6] 0.19 1.02 [0.27, 15.86] 0.19 VCT00245919 1 1.35 1.4 0.86 [0.22, 2.00] 1.09 0.27 [0.21, 2.55] 0.90 VCT00865526 1 40 1 50 0.77 [0.21, 2.55] 0.90 0.77 [0.21, 2.55] 0.90 VCT00865526 1 84 2 69 0.77 [0.21, 2.55] 0.90 0.75 [0.21, 2.55] 0.90 0.75 [0.21, 2.55] 0.90 0.75 [0.21, 2.55] 0.90 0.75 [0.21,	Langhammer B 2008	1	34	6	34		0.19[0.02, 1.51]	0.33
ab 2 2018 1 7.6 0 7.9 3.00 [127, 7.24] 0.11 Moreland JD 2003 3 56 7.5 7.5 1.45 [025, 8.23] 0.46 MCT00047437 158 670 198 674 0.97 [0.80, 11.6] 42.87 VCT0024431 1 2 0 3.2 0.14 [0.16, 2.12] 0.54 VCT00243919h 1 138 1 71 0.52 [0.03, 8.16] 0.16 VCT00243919h 3 123 0 72 4.02 [0.01, 3.22] 0.54 VCT00243919h 3 123 0 72 4.02 [0.01, 3.22] 0.16 VCT00243919h 3 123 0 72 4.02 [0.01, 3.22] 0.16 VCT00245051 4 7 2 0.75 [0.21, 2.55] 0.90 VCT00855201a 4 7 2 0.75 [0.21, 2.55] 0.90 VCT00855201a 4 7 2 0.75 [0.21, 2.55] 0.90 VCT0048601/1/VOME-BASE 1 5 0.42 [0.04, 4.51] 0.25 0.50 VCT00455021	Liu M 2018	3	68	8	62		0.37 [0.10, 1.34]	0.86
Moveland JD 2003 3 56 2 56 1.44 [10.25, 0.23] 0.48 VCT0047437 199 970 198 974 0.97 [10.80, 11.6] 42.87 VCT0047437 129 0 32 3.16 [0.14, 75.49] 0.14 VCT0024313 2 34 4 26 0.42 [0.06, 2.12] 0.54 VCT00243919h 1 138 1 71 0.52 [0.03, 6.06] 0.69 [0.24, 2.00] 10.9 VCT0045801/HOME-BASE 1 35 14 0.20 [0.01, 3.92] 0.16 0.56 [0.25, 2.00] 10.9 VCT0045801/HOME-BASE 1 35 1.4 0.20 [0.01, 3.92] 0.16 0.20 [0.01, 3.92] 0.16 VCT0045801/HOME-BASE 1 80 0.22 [0.01, 3.92] 0.16 1.02 [0.07, 15.86] 0.19 VCT004582016 4 7 2 2 0.73 [0.21, 2.55] 0.90 VCT004582017 5 6 2 2 0.73 [0.21, 2.55] 0.90 VCT004582016 1 81 2 9 0.44 [0.01, 2.58] 0.51 VCT01747	Ma C 2018 Marra S 1985	1	78	5	79 75		- 3.00 [0.12, 72.54] 1.19 [0.38, 3.73]	0.14
CCTOOQ4747 158 670 158 674 0.97 (0.80, 1.16) 42.87 NCT001763844 0 16 1 16 0.35 (0.02, 8.09) 0.14 NCT00174513 2 34 4 26 0.42 (0.08, 2.12) 0.54 NCT00243919b 3 138 1 7 0.52 (0.03, 8.16) 0.16 NCT00243919b 3 123 0 72 4.02 (0.21, 76.81) 0.16 NCT00243919b 3 123 0 72 4.02 (0.21, 76.81) 0.16 NCT00265556 1 40 1 50 0.92 (0.41, 2.06) 2.19 NCT00665501b 4 7 2 2 0.73 (0.21, 2.55) 0.90 NCT0065501b 4 7 2 2 0.73 (0.21, 2.55) 0.90 NCT01343602 1 84 2 69 0.73 (0.21, 2.55) 0.90 NCT01343602 1 84 36 0.50 (0.10, 2.58) 0.53 0.53 0.53 0.53 0.53 0.50 0.55 0.54 0.44 0.50 (0.14	Moreland JD 2003	3	58	2	56		1.43 [0.25, 8.23]	0.46
VCT00176384 0 16 1 16 0.35 0.02 8.09 0.14 VCT00184431 1 29 0.32 0.315 0.42 0.08 0.16 0.19 VCT00244513 2 34 4 26 0.42 0.08 0.21 0.55 0.16 0.19 VCT00484919 1 13 5 14 0.62 0.20 1.66 0.19 0.22 0.66 0.22 0.07 0.22 0.66 0.29 0.01 0.86 0.11 0.02 0.07 0.22 0.75 0.21 0.25 0.90 0.07 0.21 2.55 0.90 VCT00695501 4 7 2 2 0.73 0.21 2.55 0.90 VCT004552016 5 6 2 2 0.73 0.21 2.55 0.90 VCT0144706 9 177 9 185 1.04 0.42 0.24 0.14 0.10 2.55 0.90 VCT0147056 1 15 0 6 1.24 0.80	NCT00047437	189	970	198	974	•	0.97 [0.80, 1.16]	42.87
NC 100 (NS1) 1 2 3 4 2 3 4 2 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 <th1< th=""> <th1< th=""> <th1< th=""> <th1<< td=""><td>NCT00176384</td><td>0</td><td>18</td><td>1</td><td>18</td><td></td><td>0.35 [0.02, 8.09]</td><td>0.14</td></th1<<></th1<></th1<></th1<>	NCT00176384	0	18	1	18		0.35 [0.02, 8.09]	0.14
NCT00243919a 1 138 1 71 0.52 [0.03, 8.6] 0.19 NCT00243919b 3 123 0 72 4.02 [0.21, 76.81] 0.16 NCT00243901/HOME-BASE 13 12 0 72 4.02 [0.01, 3.82] 0.16 NCT006955 10 40 1 50 1.02 [0.07, 15.66] 0.16 NCT00695501 4 7 2 0.73 [0.21, 2.55] 0.90 NCT00695501b 4 7 2 0.73 [0.21, 2.55] 0.90 NCT0035501b 4 7 2 0.73 [0.21, 2.55] 0.90 NCT01343002 1 84 2 69 0.42 [0.04, 451] 0.25 NCT01343002 1 84 2 69 0.42 [0.06, 3.62] 1.75 NCT01343002 1 5 0.41 [0.01, 2.58] 0.51 0.55 NCT01343002 94 1 5 0.42 [0.06, 3.62] 0.53 NCT01343002 94 1 3 4 0.26 [0.03, 2.61] 0.55 NCT0142705 9 0.43 [0.10, 1.75] <td>NCT00184431 NCT00214513</td> <td>2</td> <td>29 34</td> <td>4</td> <td>32 26</td> <td></td> <td>0.42 [0.08, 2.12]</td> <td>0.14</td>	NCT00184431 NCT00214513	2	29 34	4	32 26		0.42 [0.08, 2.12]	0.14
VCT00249319b 3 123 0 72 4.02 [021, 76.81] 0.16 VCT00489301/ HOME-BASE 4 13 5 14 0.88 [0.29, 2.80] 1.08 VCT00265526 1 49 1 50 1.02 [0.07, 15.86] 0.19 VCT00265526 1 49 1 50 1.02 [0.07, 15.86] 0.19 VCT00265526 1 49 7 2 2 0.73 [0.21, 2.55] 0.90 VCT0026552016 5 6 2 0.73 [0.21, 2.55] 0.90 VCT01453020 1 84 2 69 0.42 [0.04, 451] 0.25 VCT01453020 1 84 2 69 0.42 [0.01, 4.11] 0.25 [0.83 VCT01473785 1 15 0 6 1.24 [0.02, 2.69] 0.83 VCT01473785 1 15 0 6 1.24 [0.02, 2.69] 0.83 VCT01473785 1 15 0 6 1.24 [0.02, 2.68] 0.83	NCT00243919a	1	138	1	71		0.52 [0.03, 8.16]	0.19
VCT004890/ HOME-BASE 4 13 5 14 0.88 [0.22, 2.60] 1.00 VCT0069574 1 40 1 50 1.02 [0.07, 15.66] 0.18 VCT0069556 1 40 1 50 0.92 [0.11, 2.65] 0.90 VCT00695501 4 7 2 2 0.73 [0.21, 2.55] 0.90 VCT00695501b 4 7 2 2 0.73 [0.21, 2.55] 0.90 VCT00695501b 4 7 2 2 0.73 [0.21, 2.55] 0.90 VCT00457206 9 177 9 185 1.04 [0.42, 2.57] 1.75 VCT01747395b 1 15 0 6 1.24 [0.06, 26.60] 0.15 VCT01747395b 1 15 0 6 1.24 [0.06, 26.60] 0.15 VCT0143501 1 21 3 14 0.26 [0.03, 2.26] 0.30 VCT0147395b 1 15 0 4 0.33 [0.01, 7.65] 0.14 VCT0	NCT00243919b	3	123	0	72		- 4.02 [0.21, 76.81]	0.16
Crono25526 1 49 1 50 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 122 <td>NCT00489801/ HOME-BASE NCT00666744</td> <td>4</td> <td>13 20</td> <td>5</td> <td>14 18</td> <td></td> <td>0.89 [0.29, 2.80]</td> <td>1.09</td>	NCT00489801/ HOME-BASE NCT00666744	4	13 20	5	14 18		0.89 [0.29, 2.80]	1.09
CCT0089555 10 80 11 80 0.92 [0.41, 2.66] 2.16 NCT00955201a 4 7 2 2 0.73 [0.21, 2.55] 0.90 NCT00955201b 4 7 2 2 0.91 [0.22, 2.54] 0.90 NCT00455201b 5 6 2 2 0.91 [0.22, 2.54] 1.03 NCT01457206 9 177 9 185 0.44 [0.04, 2.57] 1.75 NCT01457206 9 177 9 185 0.44 [0.01, 2.80] 0.15 NCT01473785b 1 15 0 6 0.124 [0.02, 3.64] 0.69 NCT01935297 2 11 5 0 0.43 [0.10, 1.85] 0.67 CCT0254015 1 21 3 14 0.28 [0.01, 7.65] 0.14 CCT0255015 1 31 14 0.28 [0.01, 7.65] 0.14 CCT0255015 1 31 14 0.28 [0.11, 7.65] 0.14 CCT025015 1 27 0.33 [0.01, 7.65] 0.14 CCT025015 1.30 1.22	NCT00825526	1	49	1	50		1.02 [0.07, 15.86]	0.19
VCT00855201a 4 7 2 2 0.75 [0.21, 2.55] 0.90 VCT00955201c 5 6 2 2 0.75 [0.21, 2.55] 0.90 VCT00955201c 5 6 2 2 0.75 [0.21, 2.55] 0.90 VCT0045201c 5 6 2 2 0.75 [0.21, 2.55] 0.90 VCT0147206 9 177 9 185 0.14 [0.01, 2.58] 0.53 VCT01473795b 1 15 0 6 1.24 [0.02, 7.60] 0.53 VCT01247395b 1 15 0 6 0.50 [0.10, 2.58] 0.53 VCT0224495 0 94 1 3 0.43 [0.10, 1.85] 0.67 VCT0224495 0 94 1 34 0.26 [0.03, 2.26] 0.30 VCT02249151 1 21 3 14 0.26 [0.03, 2.66] 0.41 VCT022491512 0 28 1 27 0.33 [0.01, 7.65] 0.14 VCT022491512 <td>NCT00895635</td> <td>10</td> <td>80</td> <td>11</td> <td>80</td> <td>-</td> <td>0.92 [0.41, 2.06]</td> <td>2.19</td>	NCT00895635	10	80	11	80	-	0.92 [0.41, 2.06]	2.19
NC1006530/16 4 7 2 2 0.75 [221, 2.53] 0.93 NC10065201c 5 6 2 0.91 [222, 2.53] 0.93 0.42 [204, 451] 0.25 NC101432020 1 84 2 69 0.42 [204, 451] 0.25 NC10143202 1 84 2 69 0.42 [204, 451] 0.25 NC101437355 1 15 0 6 1.24 [206, 286] 0.53 NC101335297 2 11 5 9 0.43 [201, 8.68] 0.56 NC10234151 1 21 31 4 0.26 [203, 2.26] 0.30 NC10255015 1 35 0 34 0.26 [203, 2.26] 0.30 NC102541152 0 28 0.33 [201, 7.65] 0.14 NC10254112 0 28 0.33 [201, 7.65] 0.14 NC10254142 117 3 114 0.33 [201, 7.65] 0.14 NC10254142 0 28 122 0.65<	NCT00955201a	4	7	2	2		0.73 [0.21, 2.55]	0.90
NCT01343602 1 84 2 69 0.42 [0.04, 4.51] 0.25 NCT0147206 9 177 9 185 1.04 [0.42, 2.57] 1.75 NCT0147395a 0 16 1 5 1.04 [0.42, 2.57] 1.75 NCT01864382 2 36 4 36 0.50 [0.10, 2.58] 0.53 NCT01864382 2 36 4 36 0.50 [0.10, 2.58] 0.53 NCT0243151 1 21 3 14 0.22 [0.03, 2.68] 0.14 NCT02550015 1 35 0 34 2.84 [0.12, 67.36] 0.14 NCT0255015 1 35 0.3 33 [0.01, 7.65] 0.14 NCT0255015 1 35 0.4 0.33 [0.01, 7.65] 0.14 NCT02541312 0 28 1.27 0.33 [0.01, 7.65] 0.14 NCT0254144 1 117 3 114 0.33 [0.01, 7.65] 0.14 NCT0254131 1.27 0.33 [0.01, 7.65] 0.14 0.33 [0.01, 7.65] 0.14 NCT0254144 1.17	NCT00955201c	4	6	2	2	-	0.73[0.21, 2.55]	1.03
VC10147206 9 177 9 185 1.04[042, 257] 17.5 VC10147206 0 16 1 5 0.14[001, 286] 0.15 VC101473955 1 15 0 6 1.24[0.06, 28.00] 0.15 VC101423257 2 38 4 36 0.50[0.10, 2.88] 0.55 VC10243151 1 21 3 14 0.28[0.01, 8.06] 0.14 VC10255015 1 35 0 34 2.84[0.12, 67.5] 0.14 VC1025413151 1 21 3 14 0.28[0.01, 7.55] 0.14 VC1025413151 1 27 0.33[0.01, 7.55] 0.14 VC1025413 0.33[0.01, 7.55] 0.14 VC10254134 0 126 122 0.20[0.01, 4.06] 0.6 0.75 0.11 0.33[0.01, 7.56] 0.14 VC10254142 0 29 1 28 0.33[0.01, 7.56] 0.14 VIENDA 0 126 12	NCT01343602	1	84	2	69		0.42 [0.04, 4.51]	0.25
VC10147395a 0 16 1 5 0.14 0.01 2.88 0.15 VC10147395b 1 15 0 6 0.50 0.10 2.88 0.15 VC10164382 2 38 4 36 0.50 0.10 1.85 0.67 VC10164382 2 38 4 36 0.50 0.10 1.85 0.67 VC10224445 0 94 1 93 0.31 0.01 6.80 0.14 VC10255015 1 35 0.34 -2.84 0.12 0.33 0.01 7.65 0.14 VC1025015 1.35 0.24 1.27 0.33 0.30 0.31 0.31 0.31 0.32 0.01 7.65 0.14 VC10250104 1 17 1 16 0.33 0.01 7.65 0.14 VC103021044 1 17 1 1 1.26 0.31 0.17 0.55	NCT01467206	9	177	9	185	-	1.04 [0.42, 2.57]	1.75
CCT01864382 2 38 4 36 0.50 [0.10. 2.58] 0.53 CCT01864382 2 11 5 9 0.43 [0.10. 1.85] 0.67 CCT02224495 0 94 1 93 0.33 [0.01. 6.95] 0.43 [0.10. 1.85] 0.67 NCT02550015 1 35 0 34 0.28 [0.03, 2.26] 0.30 NCT02550015 1 35 0 34 0.28 [0.01, 7.55] 0.14 NCT02550015 1 35 0 34 0.28 [0.01, 7.55] 0.14 NCT02550015 13 14 0.33 [0.01, 7.55] 0.14 0.33 [0.01, 7.56] 0.14 NCT02521044 1 17 1 14 0.33 [0.01, 7.56] 0.14 VEHDP1982 15 308 24 304 0.63 [0.01, 7.66] 0.14 VEHDP1982 15 308 2.40 0.33 [0.01, 7.66] 0.14 VITRTC1424 0 28 1.27 0.33 [0.01, 7.62] 0.17 Van A2005 2 17 1 1 1.26 [0.13, 1.26] 0.17 <td>NCT01747395a NCT01747395b</td> <td>0</td> <td>16 15</td> <td>1</td> <td>5</td> <td></td> <td>0.14 [0.01, 2.98]</td> <td>0.15</td>	NCT01747395a NCT01747395b	0	16 15	1	5		0.14 [0.01, 2.98]	0.15
CCT01835287 2 11 5 9 0.43 [0.10, 1.85] 0.67 NGT02224495 0 94 1 93 0.33 [0.01, 8.06] 0.14 NGT02224495 0 94 1 93 0.33 [0.01, 8.06] 0.14 NGT02224151 1 21 3 14 0.26 [0.03, 2.65] 0.33 [0.01, 7.65] 0.14 NCT0255015 1 35 0 34 2.84 [0.12, 67.36] 0.14 NCT02554152 0 28 1 27 0.33 [0.01, 7.65] 0.14 NCT0250104 1 117 3 114 0.33 [0.01, 7.65] 0.14 NCT0250120144 1 126 22 122 0.20 [0.01, 4.06] 0.16 NENDER 126 2 122 0.33 [0.01, 7.76] 0.14 VentR534 0 126 2 22 0.33 [0.01, 7.76] 0.17 VentR534 0 20 1.7 1 11 1.26 [0.13, 12.46] 0.27 VentR5400 2 17 1 14 0.33 [0.01, 7.7	NCT01864382	2	38	4	36		0.50 [0.10, 2.58]	0.53
VCT0224495 0 94 1 93 0.33 [0.01, 8.08] 0.14 VCT02441951 1 21 3 14 0.26 [0.03, 2.08] 0.14 VCT02451951 1 35 0 34 2.84 [0.12, 67.36] 0.14 VCT02550015 1 35 0 34 2.84 [0.12, 67.36] 0.14 VCT025517270 0 17 1 16 0.33 [0.01, 7.85] 0.14 VCT0255015 1 35 0 34 0.33 [0.01, 7.85] 0.14 VCT02549152 0 28 1.27 0.33 [0.01, 7.85] 0.14 VCT02549142 0 29 1.22 0.20 [0.01, 4.06] 0.66 VTRTC1424 0 29 1 28 0.33 [0.01, 7.86] 0.14 VTRTC1424 0 29 1 28 0.33 [0.01, 7.86] 0.14 VREOR Group 1991 0 60 4 57 0.11 [0.01, 2.65] 0.17 PREOR Group 1991 0	NCT01935297	2	11	5	9		0.43 [0.10, 1.85]	0.67
NCL02415151 1 21 3 14 0.26 [0.03, 2.26] 0.35 [0.01, 7.65] 0.14 NCT0255015 1 35 0 34 2.28 [0.12, 67.56] 0.14 NCT025571270 0 17 1 16 0.33 [0.01, 7.65] 0.14 NCT025571270 0 17 1 16 0.33 [0.01, 7.65] 0.14 NCT02554152 0 28 1 27 0.33 [0.01, 7.66] 0.14 NCT0254152 0 28 122 0.20 [0.01, 4.06] 0.16 0.66 [0.34, 1.19] 3.28 VEHDP 1982 128 0.33 [0.01, 7.66] 0.14 Name 0.33 [0.01, 7.66] 0.14 VIRTC1424 0 29 1 28 0.33 [0.01, 7.66] 0.14 Visen A2000 2 17 1 11 128 [0.18, 12.72] 0.54 Visen A2003 0 16 1 6 0.67 [0.11, 3.92] 0.45 Sozahl B2003 0 16 1 6 0.31 [0.01, 7.07] 0.14 Visen A2002 122 1 19 </td <td>NCT02224495</td> <td>0</td> <td>94</td> <td>1</td> <td>93</td> <td></td> <td>0.33 [0.01, 8.08]</td> <td>0.14</td>	NCT02224495	0	94	1	93		0.33 [0.01, 8.08]	0.14
NCT02571270 0 17 1 16 0.33 [0.01, 7.65] 0.14 VCT0254142 0 28 1 27 0.33 [0.01, 7.65] 0.14 VCT0254142 0 28 1 27 0.33 [0.01, 7.65] 0.14 VCT0254142 0 28 112 27 0.33 [0.01, 7.65] 0.14 VEHDP 1982 15 306 24 304 0.65 [0.34, 119] 302 VTR1534 0 126 2 22 0.20 [0.01, 4.66] 0.6 VTR17C1424 0 29 1 28 0.33 [0.01, 7.65] 0.14 Viseon A2000 2 17 1 1 1.26 [0.15, 1.46] 0.27 Van A 2013 2 127 3 126 0.67 [0.11, 3.92] 0.45 Van A2000 16 1 6 0.37 [0.01, 7.77] 0.14 Van A2013 2 127 192 [0.30, 0.01, 7.77] 0.14 Van Maddhin M2020 4 22 199 [0.30, 0.77] 0.14 Van Maddhin M2020 1 18 0 <td>NCT02413131 NCT02550015</td> <td>1</td> <td>35</td> <td>0</td> <td>34</td> <td></td> <td>- 2.84 [0.12, 67.36]</td> <td>0.30</td>	NCT02413131 NCT02550015	1	35	0	34		- 2.84 [0.12, 67.36]	0.30
VC102584192 0 28 1 27 0.33 [0.01, 7.85] 0.14 VC102584192 1 117 3 114 0.33 [0.03, 3.13] 0.28 VC102584192 15 508 24 504 0.33 [0.01, 7.85] 0.14 VC102584192 15 508 24 504 0.33 [0.01, 7.85] 0.14 VTR1534 0 126 2 122 0.20 [0.01, 4.66] 0.16 VTR1544 0 29 1 28 0.33 [0.01, 7.95] 0.14 Vana A2000 2 17 1 11 1.26 [0.01, 7.66] 0.17 PRE COR. Group 1961 0 60 4 57 0.11 [0.01, 2.06] 0.17 Pach B2003 0 16 1 6 0.67 [0.11, 3.92] 0.45 Pace IB 2003 0 16 1 6 0.16 [0.01, 3.44] 0.14 Sandarbia M 2020 4 25 2 26 1.95 [0.38, 9.72] 0.54	NCT02571270	0	17	1	16		0.33 [0.01, 7.65]	0.14
VC1032/0144 1 11 3 114 0.33 0.03 3.13 0.23 VC1032/0144 1 117 3 114 0.33 0.03 3.13 0.23 VTR1534 0 126 2 122 0.20 0.001, 7.86 0.14 VTR1544 0 29 1 28 0.33 0.01, 7.86 0.14 VTR1544 0 29 1 28 0.33 0.01, 7.86 0.14 Vann A2000 2 17 1 11 1.28 0.03 0.01, 2.05 0.17 PRE-COR.Group 1901 0 6 4 57 0.11 0.11 0.22 0.42 0.35 0.07 0.41 Steine F 2012 0 22 1 19 0.30 0.07 0.14 Savantes DM 2012a 1 16 0 0.16 0.14 0.15 0.14 0.15 0.14 0.15 0.14 0.15 0.14 0.15 0.14 0.15 0.16 0.15 0.16 0.15 0.14 <	NCT02584192	0	28	1	27		0.33 [0.01, 7.85]	0.14
TRTIS34 0 126 2 122 0.20 0.01, 4.06 0.16 TRTC1424 0 29 1 28 0.33 0.01, 7.66 0.14 VIRTC1424 0 29 1 28 0.33 0.01, 7.65 0.14 Dates 0 0 1 39 0.33 0.01, 7.65 0.14 Dates A2000 2 17 1 11 1.26 0.13, 12.46 0.27 PRE-COR, Group 1991 0 60 4 57 0.11 0.01 2.05 0.17 PaceMI B2003 0 16 1 6 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.172 0.22 0.27 0.54 0.14 0.281 0.44 0.27 0.54 0.14 0.281 0.14 0.281 0.14 0.281 0.14 0.281 0.15 5.07 0.14 0.281 0.15 5.07 0.14 0.201 0.15 5.07 0.14 0.201	NC103021044 NEHDP 1982	1	308	3 24	114 304		0.63 [0.03, 3.13]	3.62
VITRTC1424 0 29 1 28 0.33 [001, 7.96] 0.14 Visson BB 2006 0 40 1 39 0.33 [001, 7.96] 0.14 Visson A 2000 2 17 1 11 1.26 [0.51, 1.26 [0.51, 1.26] 0.17 PRE COR, Group 1991 0 60 4 57 0.11 [001, 2.05] 0.17 PRE COR, Group 1991 0 60 4 57 0.11 [001, 2.05] 0.17 PRE COR, Group 1991 0 60 4 57 0.16 [0.01, 3.44] 0.15 Standarbini M 2020 1 1 6 0.30 [0.01, 7.70] 0.14 Jandarbini M 2020 4 25 26 0.19 [0.38, 972] 0.54 Jandarbini M 2020 1 18 0 20 3.15 [0.14, 72.88] 0.14 Jarvantes DM 2012b 1 18 0 20 3.15 [0.14, 72.88] 0.14 Jarvantes DM 2012b 1 18 1 6 0.46 [0.03, 76.2] 0.15 Javantes DM 2012b 18 1 6 7 1.26 [0.66, 3.63] <td>NTR1534</td> <td>0</td> <td>126</td> <td>2</td> <td>122</td> <td></td> <td>0.20 [0.01, 4.06]</td> <td>0.16</td>	NTR1534	0	126	2	122		0.20 [0.01, 4.06]	0.16
Viteson Biz 2005 0 40 1 39 0.33 [0.01, 7.95] 0.14 Viteson A 2000 2 17 1 1 126 [0.15, 1.46] 0.27 PRE.COR. Group 1991 0 60 4 57 0.11 [0.01, 2.05] 0.17 Pal A 2013 2 127 3 128 0.67 [0.11, 3.82] 0.48 Standarbia M 2020 0 22 1 19 0.30 [0.01, 7.77] 0.14 Saddhia M 2020 4 25 2 26 193 [0.38, 9.72] 0.54 Sandarbia M 2020 4 25 2 26 1.93 [0.38, 9.72] 0.54 Sandarbia M 2020 1 18 0 20 .3.15 [0.14, 72.88] 0.14 Sarvantes DM 2012a 1 177 0 7 .1.26 [0.06, 27.82] 0.15 Swarajan ES 1981 1 173 1 83 0.44 [0.03, 7.82] 0.14 Spech F 2016 2 13 18 0.44 [0.05, 1.10] 1.42	NTRTC1424	0	29	1	28		0.33 [0.01, 7.86]	0.14
Amin Accoor 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 <td< td=""><td>Nilsson BB 2008</td><td>0</td><td>40</td><td>1</td><td>39</td><td></td><td>0.33 [0.01, 7.95]</td><td>0.14</td></td<>	Nilsson BB 2008	0	40	1	39		0.33 [0.01, 7.95]	0.14
Pail A 2013 2 127 3 126 0.67 [0.11, 3.92] 0.45 Pacahi B 2003 0 16 1 6 0.16 [0.01, 3.44] 0.15 Discript F 2012 0 22 1 19 0.30 [0.01, 7.07] 0.14 Sandsmin M 2020 4 25 2 26 1.93 [0.38, 9.72] 0.54 Sandsmin M 2020 4 25 2 26 1.93 [0.38, 9.72] 0.54 Sandsmin M 2020 4 25 2 26 1.93 [0.38, 9.72] 0.54 Sandsmin M 2020 1 18 0 20 3.15 [0.14, 72.88] 0.14 Sandamin M 2020 18 1 6 0.14 [0.00, 3.762] 0.15 Barvantes DM 2012b 0 18 6 0.14 [0.01, 3.762] 0.19 Spechia G 1996 5 120 13 118 0.49 [0.01, 5.10] 1.16 Graph C 2018 1 14 1.44 1.44 1.00 [0.61, 5.50] 0.19 G	P.RE.COR. Group 1991	0	60	4	57		0.11 [0.01, 2.05]	0.17
Docamb 2003 0 16 1 6 0.16 [001, 3.44] 0.15 Siberio F 2012 0 22 1 19 0.30 [001, 7.07] 0.14 Siberio F 2012 0 22 1 19 0.30 [001, 7.07] 0.14 Siberio F 2012 0 22 1 19 0.30 [0.01, 7.07] 0.14 Saddmin M 2020 4 25 26 3.15 [0.14, 72.88] 0.14 Salig S 2004 1 18 0 20 3.15 [0.14, 72.80] 0.15 Sarvantes DM 2012b 0 18 1 6 0.14 [0.00, 7.62] 0.15 Sarvantes DM 2012b 0 18 1 6 0.14 [0.01, 3.06] 0.15 Sarvantes DM 2012b 0 18 1 6 0.14 [0.01, 3.06] 0.15 Sarvantes DM 2012b 1 18 0.44 [0.03, 7.62] 0.19 0.16 [0.01, 1.01 [1.01 [1.42] 1.65 Sarvantes DM 2012b 1 15 0 12 2.28 [0.01, 0.05] <	Pal A 2013	2	127	3	126		0.67 [0.11, 3.92]	0.45
Name Constraint Constant Constraint Constraint	Pozehl B 2003	0	16	1	6		0.16[0.01, 3.44]	0.15
Salig S 2004 1 18 0 20 3.15 [0.14, 7.28] 0.14 Barvantes DM 2012b 1 17 0 7 1.26 [0.06, 27.82] 0.15 Savarates DM 2012b 0 18 1 6 -0.14 [0.01, 3.09] 0.15 Savarates DM 2012b 0 18 1 6 -0.14 [0.01, 3.09] 0.15 Savarates DM 2012b 0 18 1 6 -0.14 [0.01, 3.09] 0.15 Savarates DM 2012b 18 1 6 -0.14 [0.01, 3.01] 1.42 Spec FF 2016 2 13 118 -0.40 [0.05, 1.150] 0.15 Taylor-Pilae R 2012 1 15 0 12 -2.29 [0.10, 51.85] 0.15 Todd IC 1991 0.20 1 19 -0.33 [0.01, 7.72] 0.14 Velenga R P1986 1 4 4 -0.00 [0.66, 5.33] 1.84 Velenga R 1986 14 2 15 0.75 [0.51, 1.24] 7.17 Wileifman L 1975 28	Saadatnia M 2020	4	22 25	1	19 26		1.93 [0.38. 9.72]	0.14
Savantes DM 2012a 1 17 0 7 126 [006, 27.82] 0.15 Savantes DM 2012b 0 18 1 6 0.14 [001, 3.09] 0.15 Savantes DM 2012b 0 18 1 6 0.14 [001, 3.09] 0.15 Savantes DM 2012b 1 18 0.46 [003, 7.82] 0.15 Spacchia G 1996 5 120 13 118 0.46 [003, 7.82] 0.15 Spacchia G 1996 5 120 13 118 0.40 [0.15, 1.10] 1.42 Spacchia G 1996 2 13 0.15 5.00 [0.26, 96.13] 0.16 Syndor-Filae R 2012 1 15 0.12 -2.28 [0.10; 15.155] 0.15 Fold IC 1991 0 20 1 19 0.33 [0.01, 7.72] 0.14 Vedin K 2010 11 27 5.15 [0.66, 3.33] 184 Welneigae RP 1988 140 3 36 0.32 [0.03, 2.82] 0.28] 0.51 Wilnehimen L 1975 28 130	Selig S 2004	1	18	0	20		3.15 [0.14, 72.88]	0.14
Jervanes um 201/20 0 1 1 6 0.14 [0.01, 3.09] 0.15 Spacchia G 1996 1 173 18 0.44 [0.03, 7.62] 0.19 Spacchia G 1996 5 120 13 116 0.40 [0.01, 3.02] 0.42 [0.03, 7.62] 0.19 Spacchia G 1996 5 120 13 116 0.40 [0.15, 1.10] 1.42 Spac FR 2016 2 13 0 15 5.00 [0.26, 96.13] 0.16 Graph-Pilae R 2012 1 15 0 12 2.22 [0.10, 5.1155] 0.19 Godd I 1991 0 20 1 14 4 1.00 [0.06, 15.50] 0.19 Godd I 1991 0 20 1 14 4 1.00 [0.06, 15.50] 0.19 Godd I 1991 0 20 1 14 4 1.00 [0.06, 15.50] 0.19 Godd I 1991 0 20 1 12 7 1.50 [0.66, 3.33] 1.84 Welenga RP 1988 1.40 <	Servantes DM 2012a	1	17	0	7		1.26 [0.06, 27.82]	0.15
Specifia G 1996 5 120 13 118 0.44 0.10 1.10 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.11 1.42 0.12 2.29 0.10 0.51 0.12 2.29 0.10 0.51 0.15 0.15 0.15 0.11 0.11 1.42 1.44 1.44 1.44 1.44 1.44 1.44 1.00 1.00 1.05 0.15 0.10 0.05 0.11 0.20 0.11 1.27 0.11 1.27 0.11 1.27 0.11 1.27 0.11 1.27 1.21 0.33 0.01 1.27 0.13 1.27 0.13 1.27 0.13 1.27 0.13 1.27 0.23 1.20 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29	Servantes UM 2012b Sivarajan ES 1981	0	18 173	1	6 83		0.14[0.01, 3.09]	0.15 0.19
Spece RF 2016 2 13 0 15 5.00 [0.26, 96.13] 0.16 Taylor-Pilae R 2012 1 15 0 12 2.29 [0.10, 51, 85] 0.15 Teng Hc 2018 1 44 1 44 0.010 [0.06; 15:50] 0.15 Teng Hc 2018 1 44 1 44 0.30 [0.01, 7.72] 0.14 Veleng AR 2010 11 27 6 27 1.59 [0.66, 3.83] 1.84 Welenga RP 1998 1 40 3 36 0.32 [0.02, 22] 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22	Specchia G 1996	5	120	13	118		0.40 [0.15, 1.10]	1.42
Taylor-Pille R 2012 1 15 0 12 2.29 [0.10, 51.65] 0.15 Todd IC 1991 0 20 1 19 0.03 [0.01, 7.72] 0.14 Yedin K 2010 1 20 1 19 0.33 [0.01, 7.72] 0.14 Welenga R 1986 1 40 36 0.32 [0.03, 2.92] 0.29 0.29 0.29 0.29 0.14 Welenga R 1986 1 40 36 0.32 [0.03, 2.92] 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.57 1.51 0.61 0.51 1.64 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.43 0.57 0.57	Spee RF 2016	2	13	0	15		- 5.00 [0.26, 96.13]	0.16
Image means the construction of the constru	Taylor-Piliae R 2012	1	15	0	12		2.29 [0.10, 51.85]	0.15
tydein K 2010 11 27 6 27 1.56 (166, 333) 1.84 Weinega RP 1989 1 40 3 36 0.32 (103, 2.52) 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.57 0.31 1.4 1.4 7.17 1.16 0.32 0.32 0.32 0.32 0.35 0.51 1.24 7.17 1.16 0.34 0.32 0.35 0.51 1.24 7.17 1.16 0.32 0.35 0.57 1.11 2.33 0.57 1.11 2.34 0.35 1.16 0.35 1.16 0.35 1.16 0.35 1.16 1.16 0.32 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.	Todd IC 1991	1	44 20	1	44 19		0.33 [0.01. 7.72]	0.19
Molenga RP 1988 1 40 3 36 0.32 [0.03, 2.52] 0.28 Millenhamen L1975 28 130 35 122 0.79 [0.51, 1.24] 7.17 Millenhamen R1998 3 14 2 18	Tyedin K 2010	11	27	6	27	+	1.59 [0.66, 3.83]	1.84
vamenimen Li 197/5 28 130 35 122 ■ 0.79 [0.51, 1.24] 7.17 Wilenhahmen K 1988 3 14 2 18 - 1.76 [0.33, 9.38] 0.51 le Mello 2006 2 15 2 10 - 0.71 [0.11, 4.34] 0.43 los Santos M 2016 2 12 3 9 0.57 [0.11, 2.87] 0.54 Verrall 4derogeneity: c ² = 0.00, l ² = 0.00%, H ² = 1.00 vast of 0 + 0; Q(67) = 58.29, p = 1.00 vast of 0 + 0; Q(67) = 58.29, p = 1.00	Wielenga RP 1998	1	40	3	36		0.32 [0.03, 2.92]	0.29
Number No 1 No No <th< td=""><td>Wilhelmsen L 1975 Willenheimer R 1998</td><td>28</td><td>130</td><td>35</td><td>122</td><td>-</td><td>0.79 [0.51, 1.24]</td><td>7.17</td></th<>	Wilhelmsen L 1975 Willenheimer R 1998	28	130	35	122	-	0.79 [0.51, 1.24]	7.17
tos Santos M 2016 2 12 3 9 0.57 [0.11, 2.87] 0.54 Verall 0.82 [0.73, 0.93] 0.82 [0.73, 0.93] 0.82 [0.73, 0.93] 0.82 [0.73, 0.93] Verto 6, θ_1 Q(97) = 58.29, $p = 1.00$ 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00	de Mello 2006	2	14	2	10		0.71 [0.11, 4.34]	0.43
Dverall 0.82 [0.73, 0.93] reterospeneity: "= 0.00, l" = 0.00%, H" = 1.00	dos Santos M 2016	2	12	3	9		0.57 [0.11, 2.87]	0.54
leterogeneity: τ ⁱ = 0.00 (² = 0.00%, H ² = 1.00 iest of θ ₁ = θ ₁ ⊂ (97) = 58.29, p = 1.00 iest of θ = 0. τ = -3.20, p = 0.00	Overall						0.82 [0.73, 0.93]	
$e_{x}(0, 0) = 0, e_{y}(0, 1) = 30.20, p = 1.00$ $e_{x}(0, 0) = 0; z = -3.20, p = 0.00$	Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00$)%, H ² = 1 1.00	1.00			1		
	rest of $\theta_i = \theta_i$: $Q(97) = 58.29$, $p = Test of \theta = 0.7 = -3.20, n = 0.00$	1.00						

Figure 2 Forest plot on all-cause mortality. RR, risk ratio.

randomised to exercise had an SAE compared with 716 of 7768 (9.2%) control participants. The median assessment time point was at 6 months (IQR: 3–12 months). Meta-analysis showed evidence of a beneficial effect of adding exercise to the usual care (RR 0.79; 95% CI 0.71 to 0.88; p=0.0000). Visual inspection of forest plot (figure 5) and I² statistics indicated no statistical heterogeneity (I²=0%). Trials sequential analysis showed that there was enough information to confirm that exercise compared with control reduced the risk of SAEs by 21% (figure 6). We assessed this outcome results as high risk of bias (online supplemental S3 figure) and the certainty of the evidence as moderate (table 3). Funnel plot indicated no small study bias (online supplemental S4 figure). None of our preplanned subgroup analyses showed evidence of a difference (figure 7).

Quality of life

Ninety-six trials randomising 7676 participants reporting on healthrelated quality of life. The identified trials assessed seven different scales, that is, 36-Item Short Form Health Survey (SF36) Physical component, SF36 Mental component, Minnesota Living with Heart Failure Questionnaire (MLHFQ), SF12 Physical component, SF12 Mental component, Barthel Index of Activity of Daily Living and Kansas City Cardiomyopathy Questionnaire (KCCQ). Each scale was analysed separately and meta-analyses showed that adding exercise to usual care improved quality of life when assessing four of these seven scales (SF36 Mental component (MD 2.9; 95% CI 1.04 to 4.77; p=0.0000), SF36 Physical Component (MD 3.34; 95% CI 2.01 to 4.59; p=0.0000), MLHFQ (MD -1.31; 95% CI -1.88 to -0.74; p=0.0000), Barthel Index of Activity of Daily Living (MD 14.33; 95% CI 3 to 25.66; p=0.0000). However, except for the trial assessing quality of life using Barthel Index (8), the shown effect sizes were all below our predetermined minimal important differences.

Meta-analyses of the three remaining scales SF12 Physical component (MD 0.58; 95% CI -1.09 to 2.26; p=0.58), SF12 Mental Component (MD=3.69; 95% CI 0.31 to 7.06; p=0.032), and KCCQ (MD 3.67; 95% CI -1.05 to 8.38: p=0.13) did not show evidence of a difference. All meta-analyses and trial sequential analyses of quality of life data are included in online supplemental S4 text and the corresponding figures are included in online supplemental S20-S44 figure.

Secondary outcomes

Cardiovascular mortality

Twenty-three trials randomising 6068 participants reported on cardiovascular mortality. A total of 218 of 3033 (7.2%) participants randomised to exercise died due to a cardiovascular cause compared with 295 of 3035 (9.7%) control participants. The median assessment time point was 12 months (IQR: 4-36 months). Meta-analysis showed evidence of a beneficial effect of adding exercise to usual care (RR 0.75; 95% CI 0.64 to 0.89; p=0.0000). Visual inspection of forest plots and I² statistics indicated no statistical heterogeneity ($I^2=0\%$) (online supplemental S5 figure). Trials sequential analysis showed that there was enough information to confirm that exercise compared with control reduced the risk of cardiovascular mortality (online supplemental S6 figure). We assessed this outcome results as high risk of bias (online supplemental S7 figure) and the certainty of the evidence moderate (table 3). Funnel plot indicated no small study bias (online supplemental S8 figure). None of our preplanned subgroup analyses showed evidence of a difference (online supplemental S9 figure).



Figure 3 Trial sequential analysis of participants on all-cause mortality.

Myocardial infarction

Thirty-three trials randomising 6397 participants reported on myocardial infarction. A total of 113 of 3220 (3.5%) participants randomised to exercise had a myocardial infarction compared with 142 of 3177 (4.5%) control participants. The median assessment time point was at 12 months (IQR: 6–21 months). Meta-analysis showed no evidence of a difference of adding exercise to usual care (RR 0.83; 95% CI 0.65 to 1.06; p=0.86). Visual inspection of forest plots and I² statistics indicated no statistical heterogeneity

 $(I^2=0\%)$ (online supplemental S10 figure). Trials sequential analysis showed that there was not enough information to confirm or reject that exercise compared with control reduced the risk of myocardial infarction by 25% (online supplemental S11 figure). We assessed this outcome results as high risk of bias (online supplemental S12 figure) and the certainty of the evidence as low (table 3). Funnel plot indicated no small study bias (online supplemental S13 figure). None of our preplanned subgroup analyses showed evidence of a difference (online supplemental S14 figure).

Table 3 Summary of findings

Adding exercise to usual care for patie	Adding exercise to usual care for patient with hypertension, type 2 diabetes and cardiovascular diseases									
Patient or population: hypertension, type 2 diabetes and cardiovascular disease Intervention: exercise Comparison: usual care										
No of participants Certainty of the Anticipated absolute effects*										
Outcomes	(studies) Follow-up	evidence (GRADE)	Relative effect (95% CI)	Risk with usual care	Risk difference with exercise					
All-cause mortality follow-up: median 6 months	12 976 (99 RCTs)	⊕⊕⊕⊖ MODERATE†	RR 0.82 (0.73 to 0.93)	83 per 1.000	15 fewer per 1.000 (22 fewer to 6 fewer)					
Serious adverse event follow-up: median 6 months	16 241 (151 RCTs)	⊕⊕⊕⊖ MODERATE†	RR 0.79 (0.71 to 0.88)	92 per 1.000	19 fewer per 1.000 (27 fewer to 11 fewer)					
Cardiovascular mortality follow-up: median 12 months	6068 (23 RCTs)	⊕⊕⊕⊖ MODERATE†	RR 0.75 (0.64 to 0.89)	97 per 1.000	24 fewer per 1.000 (35 fewer to 11 fewer)					
Myocardial Infarction follow-up: median 12 months	6397 (33 RCTs)	⊕⊕⊖⊖ LOW†‡	RR 0.83 (0.65 to 1.06)	45 per 1.000	8 fewer per 1.000 (16 fewer to 3 more)					
Stroke follow-up: median 3.6 months	3934 (22 RCTs)	⊕⊕⊖⊖ LOW†‡	RR 0.93 (0.64 to 1.34)	28 per 1.000	2 fewer per 1.000 (10 fewer to 9 more)					

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). †Downgraded one for risk of bias, as most of the domains were unclear in risk of bias assessment.

Downgraded one for imprecision due to trial sequential analysis showing that there was not enough information to confirm or reject a RR 25%. Moreover, the meta-analysis showed wide CI. GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomised clinical trial; RR, risk ratio.

к	AV	1011
1	Εv	

-		ሞ
	Bibliotek. Protected by copyright.	Sports Med: first published as 10.1136/bjsports-2022-106002 on 30 November 2022. Downloaded from http://bjsm.bmj.com/ on November 30, 2023 at Kobenhavns Universitets

					RR		
Study	Number of Studies				with 95%	CI	p-value
Region							
High Income countries	83			•	0.83 [0.73,	0.94]	0.003
Low and Middle Income cou	ntries 15		-	•	0.71 [0.41,	1.24]	0.230
Test of group differences: Q	_b (1) = 0.28, p = 0.60						
Gender							
Both	81			•	0.85 [0.75,	0.96]	0.009
Female	1		•	_	0.33 [0.01,	7.97]	0.498
Male	16		-	•	0.66 [0.46,	0.96]	0.028
Test of group differences: Q	_b (2) = 1.82, p = 0.40						
Type of Exercise							
Dynamic Aerobic Exercise	58			•	0.83 [0.73,	0.95]	0.008
Dynamic Resistance Exercis	se 9		-	•	0.81 [0.51,	1.28]	0.357
Combined Exercise	19		-	•	0.76 [0.54,	1.07]	0.118
Stroke Functional Exercise	4			+	0.51 [0.12,	2.14]	0.357
Isometric Resistance Exercis	se 1		_		1.19 [0.38,	3.73]	0.771
Inspiratory Muscle Training	1			•	1.24 [0.06, 1	26.80]	0.893
Body Mind Therapies	6		_	•	0.85 [0.30,	2.40]	0.760
Test of group differences: Q	_b (6) = 1.14, p = 0.98						
Type of Participants							
Hypertension	3				1.01 [0.18,	5.72]	0.995
Type 2 diabetes	4		-	•	0.80 [0.40,	1.59]	0.524
Cardiovascular Disease	91			•	0.82 [0.73,	0.93]	0.002
Test of group differences: Q	b(2) = 0.06, p = 0.97						
Follow-up Duration							
Long Follow-up	36			•	0.83 [0.73,	0.94]	0.005
Short Follow-up	62			•	0.80 [0.59,	1.07]	0.127
Test of group differences: Q	_b (1) = 0.06, p = 0.81						
Overall				•	0.82 [0.73,	0.93]	0.001
Heterogeneity: τ^2 = 0.00, I ² =	= 0.00%, H ² = 1.00						
Test of $\theta_i = \theta_j$: Q(97) = 58.29	, p = 1.00						
		1/64	1/8	1 8			
Bandam offecto DerCincenian	I also have also						

Figure 4 Forest plot of subgroup analysis on all-cause mortality. RR, risk ratio.

Stroke

Twenty-two trials randomising 3930 participants reported on stroke. A total of 52 of 1986 (2.6%) participants randomised to exercise had a stroke, compared with 54 of 1948 (2.8%) control participants. The median assessment time point was at 3.6 months (IQR: 3-6.5 months). Meta-analysis showed no evidence of a difference of adding exercise to usual care (RR 0.93; 95% CI 0.64 to 1.34; p=0.69). Visual inspection of forest plots and I² statistics indicated no statistical heterogeneity $(I^2=0\%)$ (online supplemental S15 figure). Trials sequential analysis showed that there was not enough information to confirm or reject that exercise compared with control reduced the risk of stroke by 25% (online supplemental S16 figure). We assessed this outcome results as high risk of bias (online supplemental S17 figure) and the certainty of the evidence as low (table 3). Funnel plot indicated no small study bias (online supplemental S18 figure). None of our preplanned subgroup analyses showed evidence of a difference (online supplemental \$19 figure).

DISCUSSION

Our systematic review with meta-analysis and trial sequential analysis showed with moderate certainty that adding exercise to usual care reduced the risk of all-cause mortality by 18%, SAEs by 21% and cardiovascular mortality by 25% in patients with either hypertension, type 2 diabetes or cardiovascular disease. It should be noted that the intervention length (median: 3 months) was short, the intervention volume was low (median 135 mins/ week), and the follow-up period was short (median 6 months). The shown beneficial effect sizes of exercise correspond to the effect sizes of, for example, a pharmacological reduction in systolic blood pressure of 10 mm Hg.⁴⁹ Our results show that a



Figure 5 Forest plot on serious adverse events. RR, risk ratio.



Figure 6 Trial sequential analysis of participants on serious adverse events.

relatively limited amount of exercise is safe and seems to result in a reduced risk of death and SAEs within a short time period, but the long-term effects of exercise are unclear based on our

Study	Number of Studies					RR with 95%	CI	p-value
Region								
High Income countries	125					0.81 [0.73.	0.901	0.000
Low- and Middle-Income cou	intries 25			-		0.58 [0.38.	0.891	0.013
Test of group differences: Q	(1) = 2.10, p = 0.15							
Gender								
Both	131			+		0.81 [0.73,	0.90]	0.000
Female	1			_		0.33 [0.01,	7.97]	0.498
Male	18					0.65 [0.46,	0.90]	0.011
Test of group differences: Qt	(2) = 1.87, p = 0.39							
Type of Exercise								
Dynamic Aerobic Exercise	86			*		0.79 [0.70,	0.89]	0.000
Dynamic Resistance Exercis	e 13					0.82 [0.55,	1.24]	0.345
Combined Exercise	35					0.77 [0.58,	1.01]	0.059
Body Mind Therapies	8		_	•		0.58 [0.25,	1.38]	0.221
Stroke Functional Exercise	5		_	•		0.81 [0.22,	3.03]	0.757
Isometric Resistance Exercis	se 1				-	1.19 [0.38,	3.73]	0.771
Inspiratory Muscle Training	2					- 1.39 [0.17,	11.14]	0.755
Test of group differences: Q	(6) = 1.32, p = 0.97							
Type of Participants								
Hypertension	4				-	1.09 [0.30,	4.00]	0.900
Type 2 Diabetes	17			-		0.82 [0.52,	1.28]	0.382
Cardiovascular Diseases	129			•		0.79[0.71,	0.88]	0.000
Test of group differences: Q	(2) = 0.25, p = 0.88							
Follow-up Duration								
Long Follow-up	50			•		0.79 [0.70	0.891	0.000
Short Follow-up	100			-		0.79 [0.63.	0.991	0.042
Test of group differences: Q	(1) = 0.00, p = 1.00							
Overall						0.79 [0.71,	0.88]	0.000
Heterogeneity: $\tau^2 = 0.00$, $I^2 =$	0.00%, H ² = 1.00							
Test of $\theta_i = \theta_i$: Q(149) = 86.6	5, p = 1.00							
		1/64	1/8	1	8	-		

Random-effects DerSimonian-Laird model

Figure 7 Forest plot of subgroup analysis on serious adverse events. RR, risk ratio.

results. Our reported beneficial effects of exercise were independent of the duration of follow-up, type of exercise and presence of hypertension, diabetes or cardiovascular disease. However, we must acknowledge that most trials were small, and all outcome results were at high risk of bias, and the certainty of this evidence was moderate, so our results need to be interpreted with some caution. Nevertheless, our results highlight the potential role of exercise as a safe intervention in preventing risk of premature deaths and SAEs in addition to the well-documented physical and physiological changes. ^{15-17 22 50}

In contrast to our review, previous Cochrane reviews on exercise-based rehabilitation compared with no exercise reported beneficial effects for specific cardiovascular diseases (such as coronary heart disease, heart failure, stroke and stable angina) and in one review for cardiovascular mortality,²⁸ but none of these reviews showed beneficial effects on all-cause mortality.²⁴ ²⁸ ³² ³³ ⁵¹ These reviews like ours have highlighted that the trials on exercise intervention are small, usually with short follow-up, and lack reporting on clinical events and on results of high risks of bias. However, all of these reviews involved only specific types of cardiovascular disease and the inclusion was restricted to certain types of exercise intervention only. Similar to our results, the survival benefits of engaging in muscle strengthening exercise or aerobic exercise, and/or combined exercise has also been reported in US population-based cohort studies with long follow-ups of 8.75 years.⁵² The risk reduction in mortality and SAE even for short period of follow-up as presented in this review needs to be cautiously interpreted and warrants further investigation.

We also found that adding exercise to usual care was associated with small but statistically significant improvements in quality of life across SF36 Physical and Mental Domain, MLHFQ, and Barthel Index of Activity of Daily Living. However, except for Barthel Index, the improvements were below the predefined minimal important differences, which indicate that exercise may have minimal clinically important effects on quality of life. The minimal important clinical difference in this review is based on Cohen's d definition, that is, the observed SD divided by '2' which is rather conventional.⁴² Quantification of minimal important differences, especially when analysing continuous outcomes, has challenges. However, to avoid emphasising statistically significant results without importance to patients and to avoid generalising and data-driven conclusions, it is of utmost importance to predefine thresholds for clinical significance as we have done in our predefined protocol. We adopted sample dependent distributional approach as compared with sample independent-anchor-based method, which yields clinical difference, but it is not clear if they are minimal.⁵³ For instance, in our review, the minimal clinical important difference for heart failure patient assessed through KCCQ was 8.5, however, much lower minimal clinical difference score $+4.3^{54}$ and $+5.7^{55}$ has been reported. This small yet significant improvement in quality of life reported in this review is still of vital importance as health-related quality of life has been found to be a strong and independent predictor of mortality and hospitalisation across all geographic regions among heart failure patients⁵⁶ and may likely be with other cardiovascular disease too. Previous systematic reviews have shown some positive influence of adding exercise to usual care but in most cases, it is inconclusive mainly due to lack of studies.^{32 33 51} The results for quality of life scores need to be cautiously interpreted because of high statistical heterogeneity but it is a common phenomenon for continuous outcome with a high number of studies.⁵⁷

Test for subgroup differences indicated no significant difference between trials from high-income versus low-and-middle-income countries, however, it was noteworthy that only 43/248 trials (17%) were from low-income and middle-income countries. It reiterates a critical gap in evidence being generated from low-income and middle-income countries, where almost three-quarters of hypertension, type 2 diabetes and cardiovascular disease-related deaths occur.⁵⁸

Our review has several strengths. We followed our peerreviewed protocol, which was registered and published before the literature search began. We included data from both published and unpublished trials, irrespective of the trial duration. We had comprehensive search irrespective of year of publication and language. Data were extracted by five authors in pairs in order to minimise inaccuracy in data extraction. The risk of bias was assessed using Cochrane RoB1 tool, the certainty of evidence using GRADE, trial sequential analysis to control the risks of random errors and an eight-step procedure to assess if the thresholds for statistical and clinical significance were crossed.⁴⁰ The statistical and visual representation showed very low statistical heterogeneity for all-cause mortality, SAEs, and other clinical events, hence justifying pooling of all types of exercise and different types of participants in one meta-analysis. We also did not identify signs of small study bias in our review.

Our review also has limitations. All trials were classified as overall high risk of bias. For example, most of the included trials failed to define the process of randomisation, allocation concealment and lost to follow-up adequately. Blinding of participants was impossible to maintain in many exercise interventions, which may have led to different psychological and physical responses if participants believed they had been assigned to usual standard care rather than a new exercise intervention.⁴⁸ Likewise, lack of adequate blinding of outcome assessors in most trials may have overspilled trialists" preconceived notions of intervention to the participants.⁵⁹ Due to the high risks of bias, our results may overestimate the beneficial effects of exercise. However, all-cause mortality may be robust against lack of adequate blinding. The median follow-up length of the trials included in the review was short (6 months) and long-term follow-up data were not available. Further studies with long-term follow-up data may further add to the current evidence.

We also need to acknowledge that we have pooled different types of cardiovascular disease, hypertension and diabetes together, as well as different types of exercise which may lead to clinical heterogeneity. We did not identify any signs of statistical heterogeneity in the subgroup analysis, but this may partly be due to lack of power. The trials reporting allcause mortality and SAEs were predominantly trials with cardiovascular disease and showed a statistically significant beneficial effect of adding exercise to usual care. The lack of sufficient trials for hypertension and type 2 diabetes might have skewed the overall result towards the result for cardiovascular disease. Similarly, trials reporting these clinical outcomes were majorly involved in dynamic aerobic exercise. The considerable lack of trials involving other forms of exercise also needs to be accounted, as evidence has suggested that the risk of mortality may differ according to type of exercise involved.⁶⁰ Although we did not observe any significant subgroup difference in any of our analyses, it is theoretically possible that the effects of exercise differ per different types of exercise and different types of diseases. In addition, GRADE rating of the evidence for each of the types of participants and types of exercise have further highlighted that the certainty of evidence for primary outcomes ranged from low to moderate (see online supplemental S2 table). The pooling of different types of participants and different types of interventions need to be considered when interpreting our results.

The definitions of usual care differ between the included trials. Even though we did not observe any heterogeneity in our analyses, it is theoretically possible that the effects of exercise depend on the intensity of usual care. The shown effect of adding exercise to usual care may interact with how comprehensive and intensive the usual care is. Intensive usual care may have produced lower beneficial effect of exercise and vice versa.⁶¹ In case of hypertension, type 2 diabetes and cardiovascular disease, usual care often includes advice for exercise from healthcare provider; however, recent study showed that advice alone does not have substantial effect on the outcomes as compared with healthcare worker-led physical intervention.⁶² In addition, individuals with hypertension, type 2 diabetes and cardiovascular disease live with many comorbidities. Though not studied discretely in this review they may have altered the effect size. Likewise, individual physiological characteristics, mental status and attitude may have affected the uptake of exercise when added to their usual care and may have affected the outcomes of the studies. However, assessing such effects is out of the scope of this review.

We were not able to find 62 full text articles, mostly of Chinese language (online supplemental references). As per protocol, we contacted authors through email and followed up on ResearchGate wherever possible, however, no further information was available. These studies mostly include body mind therapies and are less likely to report on mortality and SAEs, and we believe it will not alter the final conclusion of this review. Furthermore, the lack of information on baseline characteristics, disease severity, concurrent medication use, exercise volume and intensities in majority of trials limits the discussion of findings of this review.

CONCLUSIONS

This review demonstrates that adding a short and lowmoderate volume exercise intervention to usual care is safe and seems to lower the risk of all-cause mortality, SAEs and cardiovascular mortality in patients with either hypertension, type 2 diabetes or cardiovascular disease. The effects of exercise on quality of life seems to be significant but the effect sizes seem minimal.

Author affiliations

¹Department of Regional Health Research, University of Southern Denmark, Odense, Denmark

²Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark

³Department of Public Health, Section for Global Health, Aarhus University, Aarhus, Denmark

⁴Unit for Health Promotion Research, University of Southern Denmark, Odense, Denmark

⁵Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Koge, Denmark

⁶Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark ⁷Department of Clinical Research, University of Southern Denmark, Odense, Denmark ⁸Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

⁹Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

Twitter Anupa Rijal @anuparijal and Tara Ballav Adhikari @NepalChirp

Contributors AR, MHO and JCJ conceived this systematic review. AR, TBA and SD conducted the literature search. AR, TBA, SD, MM and RP extracted data independently and assessed the risk of bias using the Cochrane Risk of Bias-version 1 (RoB1) in pairs. AR conducted the data analysis and data interpretation aided by EEN and JCJ. AR wrote the first draft with input from EEN, MHO and JCJ. DN, PHG provided valuable comments and amended the article. All authors read, amended and approved the final manuscript.

Funding The salary of the first author was supported by a research grant from the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation, grant number NNF17SA0031406.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Anupa Rijal http://orcid.org/0000-0003-4158-6805 Emil Eik Nielsen http://orcid.org/0000-0003-1108-9533 Tara Ballav Adhikari http://orcid.org/0000-0002-7654-5483 Mathias Maagaard http://orcid.org/0000-0002-9037-7295 Reza Piri http://orcid.org/0000-0002-6379-3373 Dinesh Neupane http://orcid.org/0000-0002-1501-2990 Janus Christian Jakobsen http://orcid.org/0000-0002-3642-2120

REFERENCES

1 Institute for Health Metrics and Evaluation (IHME). Cardiovascular Diseases- level 2 cause: IHME, University of Washington, 2019. Available: http://ghdx.healthdata.org/ gbd-results-tool?params=gbd-api-2019-permalink/d79978f279d15bcbca774ca7 a6135a19 [Accessed 19 Apr 2020].

- 2 Petrie JR, Guzik TJ, Touyz RM, Diabetes TRM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. *Can J Cardiol* 2018;34:575–84.
- 3 Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet 2010;375:2215–22.
- 4 Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet 2018;392:1923–94.
- 5 Khan MAB, Hashim MJ, King JK, et al. Epidemiology of Type 2 Diabetes Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health 2020;10:107–11.
- 6 Institute for Health Metrics and Evaluation (IHME). Diabetes mellitus type 2, 2019. Available: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019permalink/9d13a7d83d0b0498f9a7c02275cae249 [Accessed 19 Apr 2020].
- 7 Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat Rev Nephrol* 2020;16:223–37.
- 8 Schutte AE, Srinivasapura Venkateshmurthy N, Mohan S, et al. Hypertension in lowand middle-income countries. Circ Res 2021;128:808–26.
- 9 Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. *The Lancet* 2016;388:2665–712.
- 10 World Health Organization [WHO].. Hearts technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling. Geneva, Switzerland: WHO, 2018.
- 11 Colberg SR, Sigal RJ, Fernhall B, *et al*. Exercise and type 2 diabetes: the American College of sports medicine and the American diabetes association: joint position statement. *Diabetes Care* 2010;33:e147–67.
- 12 Myers J. Exercise and cardiovascular health. *Circulation* 2003;107:e2–5.
- 13 Williams B, Mancia G, Spiering W. 2018 ESC/ESH guidelines for the management of arterial hypertension. *Eur Heart J*2018;39.
- 14 Rijal A, Nielsen EE, Hemmingsen B, et al. Adding exercise to usual care in patients with hypertension, type 2 diabetes mellitus and/or cardiovascular disease: a protocol for a systematic review with meta-analysis and trial sequential analysis. Syst Rev 2019;8:330.
- 15 Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training. *Circulation* 2013;128:873–934.
- 16 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–81.
- 17 Colberg SR, Sigal RJ, Yardley JE, *et al*. Physical Activity/Exercise and diabetes: a position statement of the American diabetes association. *Diabetes Care* 2016;39:2065–79.
- 18 Grace A, Chan E, Giallauria F, et al. Clinical outcomes and glycaemic responses to different aerobic exercise training intensities in type II diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 2017;16:37.
- 19 Thomas D, Elliott EJ, Naughton GA, et al. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;2009.
- 20 Whelton SP, Chin A, Xin X, *et al*. Effect of aerobic exercise on blood pressure. *Ann Intern Med* 2002;136:493–503.
- 21 Yanai H, Adachi H, Masui Y, et al. Exercise therapy for patients with type 2 diabetes: a narrative review. J Clin Med Res 2018;10:365–9.
- 22 Pedersen BK, Saltin B. Exercise as medicine evidence for prescribing exercise as therapy in 26 different chronic diseases. *Scand J Med Sci Sports* 2015;25 Suppl 3:1–72.
- 23 Ismail H, McFarlane JR, Nojoumian AH, et al. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail 2013;1:514–22.
- 24 Saunders DH, Sanderson M, Hayes S. Physical fitness training for stroke patients. *Cochrane Database Syst Rev* 2016;8.
- 25 Ekelund U, Steene-Johannessen J, Brown WJ, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. The Lancet 2016;388:1302–10.
- 26 Jeong S-W, Kim S-H, Kang S-H, *et al*. Mortality reduction with physical activity in patients with and without cardiovascular disease. *Eur Heart J* 2019;40:3547–55.
- 27 Leitzmann MFet al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med 2007;167:2453.
- 28 Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016;143.
- 29 Powell R, McGregor G, Ennis S, *et al.* Is exercise-based cardiac rehabilitation effective? A systematic review and meta-analysis to re-examine the evidence. *BMJ Open* 2018;8:e019656.

- 30 Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116:682–92.
- 31 Lee MS, Choi T-Y, Lim H-J, et al. Tai chi for management of type 2 diabetes mellitus: a systematic review. Chin J Integr Med 2011;17:789–93.
- 32 Long L, Anderson L, Dewhirst AM, et al. Exercise-based cardiac rehabilitation for adults with stable angina. Cochrane Database Syst Rev 2018;2:CD012786.
- 33 Rees K, Taylor RS, Singh S, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2004:CD003331.
- 34 Page MJ, McKenzie JE, Bossuyt PM. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021.
- 35 Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for systematic reviews of interventions version 5. 1.0, 2011. www.handbook.cochrane.org
- 36 International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. Int Dig Health Legis 1997;48:231–4.
- 37 WHO. Global atlas on cardiovascular disease prevention and control. Switzerland, Geneva: World Health Organization (WHO), 2011.
- 38 The World Bank. World bank country and lending groups, 2021. Available: https:// datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-countryand-lending-groups
- Stata Statistical Software: Release 16 [program]: College Station, TX: StataCorp LLC.
 Jakobsen JC, Wetterslev J, Winkel P, *et al*. Thresholds for statistical and clinical significance
- in systematic reviews with meta-analytic methods. BMC Med Res Methodol 2014;14:120.
 Higgins JP, Thomas J, Chandler J. Cochrane Handbook for systematic reviews of interventions. John Wiley & Sons, 2019.
- 42 Cohen J. Statistical power analysis for the behavioural sciences. New York: Academic Press, 1988.
- 43 Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 2017;17:39.
- 44 Guyatt GH, Oxman AD, Schünemann HJ, et al. Grade guidelines: a new series of articles in the Journal of clinical epidemiology. J Clin Epidemiol 2011;64:380–2.
- 45 Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
- 46 Hayes K, Leet AS, Bradley SJ, et al. Effects of exercise training on exercise capacity and quality of life in patients with a left ventricular assist device: a preliminary randomized controlled trial. J Heart Lung Transplant 2012;31:729–34.
- 47 Kunkel D, Pickering RM, Burnett M, et al. Functional electrical stimulation with exercises for standing balance and weight transfer in acute stroke patients: a feasibility randomized controlled trial. *Neuromodulation* 2013;16:168–77.

- 48 O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439–50.
- 49 Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957–67.
- 50 Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the evidence. *CMAJ* 2006;174:801–9.
- 51 Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: cochrane systematic review and meta-analysis. Eur J Heart Fail 2010;12:706–15.
- 52 Zhao M, Veeranki SP, Magnussen CG, *et al*. Recommended physical activity and all cause and cause specific mortality in US adults: prospective cohort study. *BMJ* 2020;370:m2031.
- 53 Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. *Med Care* 2003;41:582–92.
- 54 Butler J, Khan MS, Mori C, et al. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. Eur J Heart Fail 2020;22:999–1005.
- 55 Spertus J, Peterson E, Conard MW, *et al*. Monitoring clinical changes in patients with heart failure: a comparison of methods. *Am Heart J* 2005;150:707–15.
- 56 Johansson I, Joseph P, Balasubramanian K, et al. Health-Related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries. *Circulation* 2021;143:2129–42.
- 57 Alba AC, Alexander PE, Chang J, et al. High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes. J Clin Epidemiol 2016;70:129–35.
- 58 Fan H, Song F. An assessment of randomized controlled trials (RCTs) for noncommunicable diseases (NCDS): more and higher quality research is required in less developed countries. *Sci Rep* 2015;5:13221–21.
- 59 Anthon CT, Granholm A, Perner A, *et al*. The effect of blinding on estimates of mortality in randomised clinical trials of intensive care interventions: protocol for a systematic review and meta-analysis. *BMJ Open* 2017;7:e0161 87–e87.
- 60 Sheehan CM, Li L. Associations of exercise types with all-cause mortality among U.S. adults. *Med Sci Sports Exerc* 2020;52:2554–62.
- 61 Angriman F, Masse M-H, Adhikari NKJ. Defining standard of practice: pros and cons of the usual care arm. *Curr Opin Crit Care* 2019;25:498–504.
- 62 Kettle VE, Madigan CD, Coombe A, et al. Effectiveness of physical activity interventions delivered or prompted by health professionals in primary care settings: systematic review and meta-analysis of randomised controlled trials. BMJ 2022;376:e068465.